Omer Karrar
0000-0001-6026-4073
13 papers found
Refreshing results…
One thousand patients with essential thrombocythemia: the Mayo Clinic experience
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients
Survival and Prognosis Among 301 Patients with Newly-Diagnosed Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy
Sodium-Glucose Co-Transporter-2 Inhibitor Use in the Setting of Myeloproliferative Neoplasms: Impact on Hemoglobin/Hematocrit Levels and Thrombosis Risk
ELN 2022 Favorable Genetic Risk Acute Myeloid Leukemia Treated with Venetoclax Plus Hypomethylating Agent: Predictors of Response and Survival
Calr Variant Allele Frequency in Essential Thrombocythemia: Molecular Associations and Impact on Disease Phenotype and Outcome
ASXL1 Mutation and Leukocytosis Undermine Spleen Response to Pacritinib in Myelofibrosis
Multi-Hit TP53 Mutations in Myeloid Neoplasms: Prognostic Impact of Morphologic Subtype Designation and Variant Allele Frequency
Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events
IDH1/2 inhibitor monotherapy in blast‐phase myeloproliferative neoplasms: A multicentre experience
Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia
ABO blood group type and risk of venous thrombosis in essential thrombocythemia
Missing publications? Search for publications with a matching author name.